BioXcel Therapeutics Inc (btai.o)

+ 收藏

利润表(BioXcel Therapeutics Inc)

导出到EXCEL
报表日期选择
  • 常用日期查询
  • 自定义年度查询
    日期范围
    报告期
    报告类型
    显示选项
关 闭
完整财报对比
2024年中报2024年一季报2023年年报2023年三季报2023年中报2023年一季报2022年年报2022年三季报2022年中报2022年一季报
起始日期 2024-01-012024-01-012023-01-012023-01-012023-01-012023-01-012022-01-012022-01-012022-01-012022-01-01
截止日期 2024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-31
报表类型 合并报表合并报表合并报表合并报表合并报表合并报表合并报表合并报表合并报表合并报表
报表年结日 1231123112311231123112311231123112311231
原始币种 美元美元美元美元美元美元美元美元美元美元
上市前/上市后 上市后上市后上市后上市后上市后上市后上市后上市后上市后上市后
营业收入(元) 1,686,000.00582,000.001,380,000.001,004,000.00663,000.00206,000.00375,000.00137,000.00--
 主营收入(元) 1,686,000.00582,000.001,380,000.001,004,000.00663,000.00206,000.00375,000.00137,000.00--
营业成本(元) 141,000.0080,000.001,260,000.00546,000.0034,000.009,000.0020,000.0011,000.00--
 主营成本(元) 141,000.0080,000.001,260,000.00546,000.0034,000.009,000.0020,000.0011,000.00--
毛利(元) 1,545,000.00502,000.00120,000.00458,000.00629,000.00197,000.00355,000.00126,000.00--
减:研发费用(元) 19,433,000.0011,401,000.0084,326,000.0074,392,000.0054,773,000.0027,800,000.0091,239,000.0058,780,000.0036,593,000.0018,559,000.00
减:营销费用(元) 22,715,000.0013,264,000.0083,413,000.0073,810,000.0049,467,000.0023,595,000.0068,761,000.0048,097,000.0031,175,000.00-
减:一般及行政费用(元) ---------12,921,000.00
减:其他营业费用(元) 856,000.00-4,163,000.004,163,000.00------
营业利润(元) -41,459,000.00-24,163,000.00-171,782,000.00-151,907,000.00-103,611,000.00-51,198,000.00-159,645,000.00-106,751,000.00-67,768,000.00-31,480,000.00
加:利息收入(元) 1,618,000.00947,000.005,649,000.004,703,000.003,636,000.002,015,000.002,528,000.00-219,000.0015,000.00
加:利息支出(元) -7,307,000.00-3,607,000.00-13,314,000.00-9,879,000.00-6,627,000.00-3,367,000.00-8,213,000.00-4,251,000.00-1,593,000.00-7,000.00
加:其他收入(支出)(元) 12,058,000.0032,000.00394,000.00286,000.00291,000.00-246,000.00-427,000.0053,000.00--
持续经营税前利润(元) -35,090,000.00-26,791,000.00-179,053,000.00-156,797,000.00-106,311,000.00-52,796,000.00-165,757,000.00-110,949,000.00-69,142,000.00-31,472,000.00
持续经营净利润(元) -35,090,000.00-26,791,000.00-179,053,000.00-156,797,000.00-106,311,000.00-52,796,000.00-165,757,000.00-110,949,000.00-69,142,000.00-31,472,000.00
净利润(元) -35,090,000.00-26,791,000.00-179,053,000.00-156,797,000.00-106,311,000.00-52,796,000.00-165,757,000.00-110,949,000.00-69,142,000.00-31,472,000.00
归属于母公司股东净利润(元) -35,090,000.00-26,791,000.00-179,053,000.00-156,797,000.00-106,311,000.00-52,796,000.00-165,757,000.00-110,949,000.00-69,142,000.00-31,472,000.00
归属于普通股股东净利润(元) -35,090,000.00-26,791,000.00-179,053,000.00-156,797,000.00-106,311,000.00-52,796,000.00-165,757,000.00-110,949,000.00-69,142,000.00-31,472,000.00
每股收益
 基本每股收益-普通股(元) -0.99-0.87-6.15-5.40-3.68-1.84-5.92-3.96-2.47-1.12
 摊薄每股收益-普通股(元) -0.99-0.87-6.15-5.40-3.68-1.84-5.92-3.96-2.47-1.12
全面收益总额(元) -35,090,000.00--------69,142,000.00-31,472,000.00
 本公司拥有人占全面收益总额(元) -35,090,000.00---------
公告日期 2024-08-062024-05-092024-03-222023-11-142023-08-142023-05-092023-03-162022-11-142022-08-112022-05-09
会计准则 美国会计准则美国会计准则美国会计准则美国会计准则美国会计准则美国会计准则美国会计准则美国会计准则美国会计准则美国会计准则
审计意见
核数师

前瞻产业研究院